Thermostable Vaccines Market

Thermostable Vaccines Market Overview

The thermostable vaccines market is estimated to be worth $XX  billion in 2021 and is expected to grow at compounded annual growth rate (CAGR) of 40% during the forecast period. Data presented by the WHO indicates that the current global vaccination coverage is nearly 85% this is believed to prevent close to three million deaths from diseases, such as diphtheria, tetanus, whooping cough and measles. However, it has been reported that 25% of vaccines are damaged due to cold chain logistics malfunction (improper distribution and shipping). In some countries, about 80% of the drugs are estimated to lose their potency due to inadequate temperature control during their cold chain transportation. For some vaccines, even the slightest variations in temperature / storage conditions can adversely alter product integrity and / or viability. Over time, technological advancements in the methods of biologics development and manufacturing have prompted the developers to explore the potential of thermostable vaccines and thermostable biologics. Thermostable vaccines can be stored at room temperature for prolonged period of time, thereby eliminating the need for cold chain requirements in storage and transportation. This enables reduction in costs incurred during storage and transportation and, subsequently, the overall costs involved in mass immunization projects. In addition, it allows the suppliers to deliver the products in safe and convenient manner even to far-flung destinations.

At present, several biopharmaceutical companies and clinical research institutes are engaged in the development of thermostable vaccines and thermostable biologics, taking into consideration the rising global population, growing demand for vaccines and specific requirements of large-scale immunization initiatives. Moreover, significant efforts are being put into the development of technologies / devices, which enables transition of conventional vaccines to thermostable vaccines. The market has witnessed substantial partnership activity over the last few years. The activity in this segment of the industry has also attracted the attention of both private and public sector investors / investment funds, which have extended financial support to the initiatives of capable developer companies. Driven by the substantial progress in research in thermostable vaccines market, encouraging clinical trial results, and ongoing technological advancement, the thermostable vaccines and thermostable biologics market is anticipated to witness a commendable market growth during the forecast period.

Key Companies in Thermostable Vaccines Market 

Examples of key companies engaged in thermostable vaccines market (which have also been profiled in this market report; the complete list of companies is available in the full report) include Allena Pharmaceuticals, Amarillo Biosciences, Vaxart, Tiziana Life Sciences, Diabetology (a subsidiary of Proxima Concepts), Biocon and Serum Institute of India. This market report includes an easily searchable excel database of all the companies providing thermostable vaccines and biologics, worldwide.

Recent Developments in Thermostable Vaccines Market:

Several recent developments have taken place in the field of thermostable vaccines market. We have outlined some of these recent initiatives below. These developments, even if they took place post the release of our market report, substantiate the overall market trends that have been outlined in our analysis.

• In May 2026, Soligenix reported that its thermostable vaccine platform could support rapid development of a Bundibugyo virus vaccine amid ongoing Ebola outbreaks in Central Africa.
• In May 2026, Lamark Biotech secured INR 6.5 crore in seed funding to advance its ProteoStrong platform, designed to stabilize protein-based therapeutics without refrigeration. The investment will support development of long shelf-life biologics, including applications relevant to vaccines, aiming to improve accessibility and distribution in regions lacking reliable cold-chain infrastructure.
• In January 2026, Stablepharma entered into development and licensing agreement with AFT Pharmaceuticals to create fridge-free injectable products using Stablepharma’s thermostable technology.

Scope of the Report

The "Thermostable Vaccines Market: Distribution by Type of Molecule (Vaccines and Proteins), Target Indications (Covid-19, Diabetes, Enteric Hyperoxaluria, Norovirus Infection and Rotavirus Infection), Type of Therapy, Key Players and Key Geographical Regions (North America, Europe and Asia Pacific and Rest of the World): Industry Trends and Global Forecasts, 2021-2035" market report features an extensive study of the current market landscape, market size, market forecast and future opportunities for the players involved in the development of thermostable vaccines and biologics for the treatment of a variety of disease conditions. The market research report presents an in-depth analysis, highlighting the capabilities of various stakeholders engaged in thermostable vaccines market, across different geographies.

Amongst other elements, the market report includes:

• An overview of thermostable vaccines market, featuring a detailed analysis of pipeline molecules, based on several relevant parameters, such as type of molecule, type of formulation, type of manufacturing technology, trial phase (clinical, preclinical and discovery), route of administration, type of storage conditions, type of disease indication (Covid-19, diabetes and others), and target therapeutic area (infectious diseases, metabolic disorders, and others). It also includes information on the completed, ongoing and planned clinical trials for thermostable vaccines and biologics, sponsored by various industry players. It also provides insights on developer landscape along with the analysis based on several parameters, including year of establishment, company size, location of headquarters.
• An insightful competitiveness analysis of thermostable vaccines and biologics developers, taking into consideration the supplier strength (based on expertise of the manufacturer), product portfolio strength, portfolio diversity, and number of area(s) of application.
• A detailed analysis of close to 150 peer-review, scientific articles related to research on thermostable vaccines and biologics, such as year of publication, type of publication focus area (therapeutic area), impact factor, most popular author and most popular journals.
• An analysis of the partnerships that have been inked by various stakeholders engaged in the development of thermostable vaccines and biologics, during the period 2015-2021, covering product development agreements, research and development agreements, licensing agreements, clinical trial agreement, licensing and manufacturing agreement, product development and commercialization manufacturing agreements, joint venture, product development and commercialization, acquisition and other types of partnership deals. 
• An analysis of the investments made at various stages of development of the companies engaged in thermostable vaccines market, covering instances of debt financing, equity investments, Secondary offerings, seed funding, award/grant funding, post-IPO Debt, post-IPO Equity, private equity and other types of funding deals. 
• Tabulated profiles of the key players providing thermostable vaccines and biologics. Each profile includes an overview of the company, thermostable product portfolio, recent developments, and an informed future outlook.

One of the key objectives of this market report is to provide a detailed market forecast analysis in order to estimate the existing market size and future opportunity of thermostable vaccines market during the forecast period. Based on multiple parameters, such as target patient population, likely adoption rates and expected pricing, we have provided informed estimates on the financial evolution of the market for the forecast period 2021-2035. For this purpose, we have segmented the future opportunity across the following market segments: Type of Molecule (Vaccines and Proteins), Target Indications (Covid-19, Diabetes, Enteric Hyperoxaluria, Norovirus Infection and Rotavirus Infection), Type of Therapy, Key Players, and Key Geographical Regions (North America, Europe and Asia Pacific and Rest of the World). To account for uncertainties and to add robustness to our model, we have provided three market forecast scenarios, portraying the conservative, base and optimistic tracks of the anticipated industry’s growth.